Wall Street Zen Upgrades VistaGen Therapeutics (NASDAQ:VTGN) to Hold

VistaGen Therapeutics (NASDAQ:VTGN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on the company. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a report on Wednesday, December 17th. Finally, Jefferies Financial Group restated a “hold” rating and set a $0.90 price target (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, VistaGen Therapeutics has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Stock Down 7.2%

NASDAQ VTGN opened at $0.51 on Friday. The firm has a market cap of $20.03 million, a P/E ratio of -0.27 and a beta of 0.33. The company’s 50 day moving average is $1.17 and its 200-day moving average is $2.80. VistaGen Therapeutics has a 12-month low of $0.43 and a 12-month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.14 million. Equities analysts expect that VistaGen Therapeutics will post -1.77 EPS for the current year.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of large investors have recently added to or reduced their stakes in VTGN. State Street Corp boosted its holdings in shares of VistaGen Therapeutics by 25.0% in the 4th quarter. State Street Corp now owns 121,114 shares of the company’s stock worth $80,000 after purchasing an additional 24,256 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in VistaGen Therapeutics by 123.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 151,874 shares of the company’s stock worth $101,000 after buying an additional 83,857 shares during the last quarter. AdvisorShares Investments LLC boosted its stake in VistaGen Therapeutics by 20.9% in the fourth quarter. AdvisorShares Investments LLC now owns 250,188 shares of the company’s stock worth $166,000 after buying an additional 43,190 shares in the last quarter. Geode Capital Management LLC boosted its stake in VistaGen Therapeutics by 18.3% in the fourth quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock worth $234,000 after buying an additional 54,556 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in shares of VistaGen Therapeutics during the third quarter worth approximately $73,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Key Stories Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Q3 results beat consensus on both EPS and revenue (reported loss $0.45/sh vs. est. $0.51; revenue $0.30M vs. est. $0.14M), which is supportive for the stock as it shows slightly better-than-expected financial performance. Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results
• Neutral Sentiment: Management provided a corporate update saying it reviewed PALISADE-3 data and implemented “moderate refinements,” language that is ambiguous for program outlook until full details from the company/meeting are disclosed; investors will look to the earnings call/transcript for color. Earnings Press Release / Call Materials Q3 2026 Earnings Call Transcript
• Negative Sentiment: A large cluster of investor alerts and class-action solicitations from multiple law firms (Robbins LLP, Schall Law Firm, Rosen, Pomerantz, DJS, Bernstein Liebhard, Gross, etc.) allege Vistagen misled investors about trial viability and seek lead plaintiffs — this increases legal overhang, raises potential litigation costs, and is the most likely proximate cause of downward pressure on the stock. Representative notices: Robbins LLP Notice Schall Law Firm Notice DJS Law Group Notice

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.